TMEM16A/ANO1: Current Strategies and Novel Drug Approaches for Cystic Fibrosis
Cystic fibrosis (CF) is the most common of rare hereditary diseases in Caucasians, and it is estimated to affect 75,000 patients globally. CF is a complex disease due to the multiplicity of mutations found in the CF transmembrane conductance regulator (CFTR) gene causing the CFTR protein to become d...
Guardado en:
Autores principales: | Christie Mitri, Himanshu Sharma, Harriet Corvol, Olivier Tabary |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/63e306b9919c4de784585f452d0ec962 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
CFTR Protein: Not Just a Chloride Channel?
por: Laurence S. Hanssens, et al.
Publicado: (2021) -
Obesity in cystic fibrosis
por: Katherine A. Kutney, et al.
Publicado: (2021) -
XV-2c and KM: 19 haplotype analysis in Chilean patients with cystic fibrosis and unknown CFTR gene mutations
por: REPETTO,GABRIELA M, et al.
Publicado: (2007) -
Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives
por: Schmidt BZ, et al.
Publicado: (2016) -
Long-Term Outcomes in Real Life of Lumacaftor–Ivacaftor Treatment in Adolescents With Cystic Fibrosis
por: Stéphanie Bui, et al.
Publicado: (2021)